Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study
This study was registered at clinicaltrials.gov, with NCT02466243. Study registration was first submitted on June 2, 2015.
Authors
- Laís Lopes Almeida Gomes (ORCID: https://orcid.org/0000-0001-5396-4362)
- Geeta Ahuja (ORCID: https://orcid.org/0000-0002-8204-7659)
- D Faden (ORCID: https://orcid.org/0000-0002-2712-9352)
- Victoria P. Werth (ORCID: https://orcid.org/0000-0003-3030-5369)
- Caroline J. Stone (ORCID: https://orcid.org/0000-0002-1697-1659)
- Barbara White (ORCID: https://orcid.org/0000-0003-4679-665X)
- Rui Feng (ORCID: https://orcid.org/0000-0003-4151-7228)
- Joy Poroye
- Lillian Xie (ORCID: https://orcid.org/0009-0006-2163-5170)
Institutions
- Corbus Pharmaceuticals (United States) (US)
- Philadelphia VA Medical Center (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- JID Innovations
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1016/j.xjidi.2024.100311
- Citations
- 4
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 1.79
Funders
- U.S. Department of Veterans Affairs
- Office of Research and Development
- National Institutes of Health